Brief: Sun Pharma - Us FDA Accepts SBLA For Ilumya For Active Psoriatic Arthritis
March 16 (Reuters) - Sun Pharmaceutical Industries Ltd SUN.NS: SUN PHARMA - US FDA ACCEPTS SBLA FOR ILUMYA FOR ACTIVE PSORIATIC ARTHRITIS SUN PHARMA - FDA REGULATORY ACTION DATE FOR THIS SBLA IS EXPECTED BY OCT 29 2026 Source text: ID:nBSE9fxgD Further company coverage: SUN.NS ((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Sun Pharmaceutical Industries
See all newsROI-US blue wave reshapes Asia's winners and losers: Manishi Raychaudhuri
Brief: Sun Pharma Clarifies Regarding News Report Relating To Company's Assam Facility
Street View: India's Sun Pharma Organon buy, psoriasis drug are risk factors
India orders Sun Pharma to halt eye-care drug production at plant after quality lapses
India orders Sun Pharma to halt eye-care drug production at plant after quality lapses